Algeria will soon require pharmaceutical companies to submit a tax clearance certificate with all files lodged with the National Agency for Pharmaceutical Products, making it a mandatory condition for administrative acceptance. This directive instructs all pharmaceutical manufacturers to include a tax clearance certificate confirming the payment of duties in every file submitted to the National Agency for Pharmaceutical Products to obtain administrative approval. The measure aims to ensure compliance with tax obligations as part of the licensing process for pharmaceutical products within the country, establishing a foundational requirement for all regulatory interactions. This new mandate shows the Algerian authorities' commitment to reinforcing financial accountability across the pharmaceutical sector.
Scope of New Tax Certificate Rule
Any file submitted without this required tax clearance certificate will be considered inadmissible and will not be processed by the National Agency for Pharmaceutical Products' competent departments. This strict adherence policy notes the importance of the certificate for any regulatory engagement. The new regulation applies broadly across various pharmaceutical and medical device procedures, ensuring full coverage of the industry's operations.
This includes applications for the registration of pharmaceutical products and the approval of medical devices, which are critical steps for market entry. The scope also extends to the renewal, amendment, or transfer of existing registration and approval decisions, covering the entire lifecycle of authorized products. The requirement encompasses advertising visas, their subsequent renewal, and all licenses or regulatory procedures that are subject to associated fees, ensuring that all financial obligations are met across a wide array of activities. This full application ensures that all aspects of pharmaceutical business operations are subject to the new tax compliance verification.
Implementation and Grace Period
The Ministry of Pharmaceutical Industry issued Directive No. 44/26 on May 18, 2026, formalizing the new requirement. The directive includes a transitional period of three months from its issuance date. This grace period allows companies to regularize their tax situation, providing a window for entities to ensure full compliance without immediate disruption. After this three-month window, the tax clearance certificate will become fully mandatory for the acceptance of any file submitted to the National Agency for Pharmaceutical Products, making it an indispensable part of the submission process. This transitional period is intended to facilitate a smooth integration of the new requirement for all pharmaceutical manufacturers.
Regulatory and Legal Context
The new requirement for tax clearance certificates forms part of the implementation of Order No. 21-07, issued on June 8, 2021, which pertains to the Supplementary Finance Law for 2021. The measure is also linked to the provisions of Law No. 24-08 of November 24, 2024, concerning the Finance Law for 2025. These legislative frameworks provide the legal backbone for the enhanced financial oversight. Algeria has been accelerating reforms aimed at modernizing its regulatory framework within the pharmaceutical sector. These reforms aim to encourage local pharmaceutical production, improve the monitoring of imported products, and reinforce compliance with international quality standards. The tax clearance mandate aligns with broader efforts to streamline regulatory processes and ensure financial accountability across the industry, contributing to a more transparent and strong market environment.
Related Regulatory Updates
In parallel with the tax clearance directive, guidelines on regulatory trust and mutual recognition practices for Good Manufacturing Practices (GMP) inspections have been made available on the website of the National Agency for Pharmaceutical Products. This update provides pharmaceutical companies with essential information regarding inspection standards and acceptance criteria, aiming to streamline regulatory processes within the sector. These guidelines are designed to foster greater confidence in manufacturing practices and facilitate international cooperation, further enhancing the overall regulatory landscape for pharmaceutical products in Algeria.
